Table 3. Subgroup analysis on primary diseases.
Short-term treatment | Long-term treatment | |||
RR (95% CI) | P for interaction | RR (95% CI) | P for interaction | |
All stroke | ||||
Prior stroke/TIA | 0.69 (0.58–0.81) | 0.12 | 0.84 (0.71–0.99) | 0.58 |
Other vascular event/risk | 0.83 (0.70–0.99) | 0.79 (0.70–0.89) | ||
Ischemic stroke | ||||
Prior stroke/TIA | 0.68 (0.57–0.81) | 0.12 | 0.78 (0.66–0.93) | 0.78 |
Other vascular event/risk | 0.84 (0.69–1.04) | 0.76 (0.67–0.86) | ||
Hemorrhagic stroke | ||||
Prior stroke/TIA | 1.00 (0.38–2.66) | 0.97 | 1.56 (0.86–2.84) | 0.43 |
Other vascular event/risk | 0.98 (0.69–1.39) | 1.15 (0.73–1.84) | ||
Major bleeding | ||||
Prior stroke/TIA | 0.88 (0.32–2.41) | 0.64 | 1.70 (1.31–2.22) | 0.31 |
Other vascular event/risk | 1.12 (0.92–1.37) | 1.47 (1.31–1.64) | ||
Intracranial bleeding | ||||
Prior stroke/TIA | NA | NA | 1.56 (0.83–2.95) | 0.66 |
Other vascular event/risk | 0.92 (0.66–1.30) | 1.87 (1.19–2.93) |
CI: confidence interval; NA: not available; RR; relative risk; TIA: transient ischemic attack.